News Breaks |
|
|
| January 22, 2013 |
| 07:36 EDT |  | AMRN | Amarin publishes additional marker data from MARINE, ANCHOR Phase 3 trials
Amarin announced that additional data from its pivotal MARINE and ANCHOR Phase 3 clinical trials are now available electronically through PubMed and are expected to be published in the print issue of the American Journal of Cardiovascular Drugs in February. The publication reports the effects of Vascepa capsules, alone and in combination with statin therapies, on inflammatory markers associated with cardiovascular disease and atherosclerosis in hypertriglyceridemic patients. In addition to the previously reported favorable lipid effects of Vascepa on hypertriglyceridemic patients in the MARINE and ANCHOR studies, this newly published analysis of these studies shows that Vascepa 4g/day significantly decreased levels of several inflammatory markers relative to placebo, including oxidized low-density lipoprotein, lipoprotein-associated phospholipase A2, and high sensitivity C-reactive protein. |
|
|
News For AMRN From The Last 14 Days Check below for free stories on AMRN the last two weeks. |
|
|
| May 23, 2013 |
| 11:55 EDT |  | AMRN | Options with decreasing implied volatility: AEGR PXP AMRN DSX ACT
 Subscribe for More Information |
|
| May 22, 2013 |
| 11:56 EDT | | AMRN | Options with decreasing implied volatility: WCRX NTI PXP AMRN BBY
|
|
| 06:07 EDT | | AMRN | Amarin announces patent allowance related to combination of Vascepa, Statin
Amarin announced that the United States Patent and Trademark Office has published notification of a Notice of Allowance for Amarin's U.S. Patent Application Serial Number 13/417,899 titled "Pharmaceutical Compositions Comprising EPA and a Cardiovascular Agent and Methods of Using the Same." This application includes claims intended to protect the Vascepa indication approved by the FDA based on Amarin's MARINE clinical trial results specifically those results seen in patients on statin therapy. The claims in this allowed application cover a method to reduce triglycerides in subjects having a triglyceride level of 500mg/dl to 1500mg/dl who are also receiving statin therapy using an amount of Vascepa effective to reduce triglycerides without substantially increasing low density lipoprotein cholesterol. |
|
| May 21, 2013 |
| 11:41 EDT | | AMRN | Options with decreasing implied volatility: SGMO WCRX NTI TSLA AMRN
|
|
| May 17, 2013 |
| 14:12 EDT | | AMRN | Amarin shares slip after FDA updates Orange Book
Subscribe for More Information |
|
| May 15, 2013 |
| 11:04 EDT |  | AMRN | Amarin management to meet with Lazard Capital
Meeting to be held in the Mid-Atlantic area on May 16 hosted by Lazard Capital. |
|
| May 13, 2013 |
| 12:52 EDT | | AMRN | Amarin strength attributed to MassHealth drug list addition
Subscribe for More Information |
|
|
|
|
|
